Skip to main content

Neoplasms, Mesothelial clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • VT3989 in Patients With Metastatic Solid Tumors

    open to eligible people ages 18 years and up

    This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

    at UCSF

Our lead scientists for Neoplasms, Mesothelial research studies include .

Last updated: